Skip to content

Comparison of infection risk in trauma patients transfused with leukoreduced vs non-leukoreduced blood

A Randomized Control Trial for evaluation of effects of leukoreduced blood transfusion on infection risk in severely injured trauma patient

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/08/020831
Enrollment
300
Registered
2019-08-21
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: S00-T88- Injury, poisoning and certain other consequences of external causes

Interventions

Intervention1: Leukoreduced blood component transfusion: Blood components will be leucofiltered during processing and storage using commercially available leukofilter for blood components Control Inte

Sponsors

AIIMS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: all patients above 18 years of age receiving RBC transfusion within 24 hours of admission.

Exclusion criteria

Exclusion criteria: 1) Patients with an anticipated survival of less than 48 hours 2) Isolated head injury patients 3) Received blood transfusion elsewhere 4) Presence of active infection 5) Pregnant females and jail inmates will be not eligible for randomization. 6) Patient with Rh(D) negative groups

Design outcomes

Primary

MeasureTime frame
Primary outcome will include development of all hospital acquired infections [urinary tract infections (UTI), bloodstream infections (BSI), pneumonia (PNEU), ventilator-associated infections (VAE), and surgical site infections (SSI)] as defined by CDC/NHSN surveillance definitionTimepoint: Till the time of discharge or hospital death whichever is earlier

Secondary

MeasureTime frame
Monitoring of the quantitative levels of sTREM and procalcitonin measured in all patients. Proportion of patient showing values above cut-off limit shall be considered as having infectionTimepoint: Till the time of discharge or death whichever is earlier

Countries

India

Contacts

Public ContactDr Rahul Chaurasia

All India Institute of Medical Sciences

drrahulchaurasia@gmail.com9560345917

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026